Skip to content
In the Clinic: Triple Combination CFTR Modulation episode artwork

Jun 2, 2020 25 min

In the Clinic: Triple Combination CFTR Modulation

from eCysticFibrosis Review

Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who’s most likely to receive them? In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s Anschutz Medical Campus, takes us to the clinic to discuss some answers. Take our post-test to claim CME credits. To read a companion newsletter click here.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

In the Clinic: Triple Combination CFTR Modulation

0:00 25:17

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of eCysticFibrosis Review?

This episode is 25 minutes long.

When was this eCysticFibrosis Review episode published?

This episode was published on June 2, 2020.

Can I download this eCysticFibrosis Review episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.